RTZ-GLP3 Research Vials | 60 mg & 30 mg

Read the RTZ-GLP3 and retatrutide research guide. Explore the receptor pathways, primary studies and evidence limitations.

RTZ-GLP3 (60 mg or 30 mg Vial) is supplied for controlled laboratory evaluation within Weight Loss / Metabolic Research studies.

• Research material: RTZ-GLP3
• Listed strength and format: 60 mg or 30 mg lyophilized research vial
• Research focus: GIP, GLP-1, and glucagon receptor-signaling models
• Research category: Weight Loss / Metabolic Research

RTZ-GLP3 identity and receptor research

RTZ-GLP3 is SRP’s listing name for retatrutide research material. The 2022 LY3437943 discovery study describes activity at GIP, GLP-1 and glucagon receptors using laboratory models and early clinical research. The study does not establish the identity or performance of a supplied SRP lot.

Compare the compound before the amount

Tirzepatide research vials concern a different, dual-receptor compound. RTZ-GLP4 is a separate custom blend containing 10 mg GLP3-Reta and 2 mg PEG-MGF. This RTZ-GLP3 page offers 30 mg and 60 mg total-vial amounts, with current price and availability shown for the selected option. Ask SRP about RTZ-GLP3 product details.

For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.